• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

National Institutes of Health

NIH launches effort to combat type 2 diabetes in young people

October 10, 2024 By Sean Whooley

NIH National Institutes of Health

The National Institutes of Health (NIH) launched a nationwide consortium to address the rise in youth diagnosed with type 2 diabetes. According to a press release, NIH expects that trend — which it observed over the past two decades — to continue moving forward. It aims to advance understanding of the biologic, social, and environmental […]

Filed Under: Clinical Trials, Diabetes, Featured, Pediatrics, Research & Development Tagged With: National Institutes of Health

Satio wins $3.5M contract to develop at-home transdermal drug delivery device

September 28, 2023 By Sean Whooley

Satio SatioRx

Satio announced that a National Institutes for Health agency awarded it a $3.5 million Small Business Innovation Research (SBIR) contract. Awarded by the NIH’s Advanced Research Projects Agency for Health (ARPA-H), the contract helps the company develop SatioRx. This drug delivery device, compact and inexpensive, features disposable microneedle components for precise delivery. It remotely enables […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Technology Tagged With: ARPA-H, National Institutes of Health, Satio

NIH funds Illinois Tech project using machine learning to fully automate insulin delivery

December 9, 2022 By Sean Whooley

Illinois Tech artificial pancreas machine learning insulin delivery diabetes

Researchers at Illinois Institute of Technology received $1.2 million from the NIH to develop a machine learning system for an artificial pancreas’ insulin delivery. Chemical engineering professor Ali Cinar leads the project to ease the burden on those with type 1 diabetes. NIH funding covers four years for developing the machine learning system. The researchers […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Funding Roundup, Patient Monitoring, Technology Tagged With: Illinois Institute of Technology, Illinois Tech, National Institutes of Health

PharmaJet wins NIH grant to evaluate needle-free delivery of HPV immunization

November 29, 2022 By Sean Whooley

PharmaJet Tropis needle-free intradermal injection system

PharmaJet announced today that it received a grant worth $800,000-plus from the NIH to evaluate its needle-free injection system. Golden, Colorado-based PharmaJet picked up a Phase II grant from the NIH (National Institutes of Health). It allows the company to evaluate the immunogenicity of the intradermal administration of human papillomavirus virus (HPV) vaccine. The study […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Preclinical Trials Tagged With: National Institutes of Health, PharmaJet

Rescue Biomedical wins $2.8M grant for nalaxone-releasing implant for opioid overdoses

October 6, 2022 By Sean Whooley

Rescue Biomedical Purdue opioid use disorder drug delivery system

Rescue Biomedical announced today that it received a $2.8 million grant from the National Institutes of Health for its opioid overdose treatment. West Lafayette, Indiana received a Fast-Track Small Business Innovation Research, or SBIR, grant from the NIH. The company develops technology that detects when a person is overdosing on an opioid and delivers naloxone […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Implants, Pharmaceuticals Tagged With: National Institutes of Health, Purdue University, Rescue Biomedical

Regeneron touts results of NIH-sponsored EYLEA injection study

March 31, 2021 By Sean Whooley

Regeneron - updated

Regeneron Pharmaceuticals (NSDQ:REGN) announced data supporting the use of its EYLEA injection in NPDR patients. Protocol W, a NIH-sponsored trial to evaluate the EYLEA (aflibercept) injection in patients with moderate to severe non-proliferative diabetic retinopathy (NPDR), without center-involved diabetic macular edema (CI-DME), had its initial results published in JAMA Ophthalmology. At two years, the primary […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: National Institutes of Health, Regeneron

Fauci: Hundreds of millions of COVID-19 vaccine doses could be ready in January

April 30, 2020 By Nancy Crotti

coronavirus COVID-19

Dr. Anthony Fauci said this morning that hundreds of millions of doses of a vaccine for COVID-19 could be ready by January. In an interview on the Today Show, the director of the National Institute of Allergy and Infectious Diseases said that a vaccine candidate is in the first phase of a clinical trial. If the second […]

Filed Under: Business/Financial News, Clinical Trials, Hospital Care Tagged With: coronavirus, COVID-19, Gilead Sciences, National Institutes of Health

NIH study: Tandem Diabetes artificial pancreas bests other treatments

October 17, 2019 By Sean Whooley

Tandem Diabetes Care - updated logo

A pivotal trial funded by the National Institutes of Health found that an artificial pancreas system from Tandem Diabetes Care (NSDQ:TNDM) was more effective than existing treatments for people with Type 1 diabetes. The Tandem system combines its t:slim X2 insulin pump and Control-IQ advanced hybrid closed-loop technology with a continuous glucose monitor made by DXCM, […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured Tagged With: National Institutes of Health, Tandem Diabetes Care

Louisiana prisoners may get non-FDA-approved naltrexone implant

May 8, 2019 By Nancy Crotti

BioCorRx updated logo

This article has been updated to clarify the BioCorRx’s role in the program. The Louisiana Department of Corrections is working with BioCorRx (OTC:BICX) to offer soon-to-be-released inmates an opioid addiction treatment implant that has not been approved by the FDA. The implant, which contains a compounded form of naltrexone, is one of several medication-assisted options being […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Research & Development, Uncategorized Tagged With: BioCorRx, National Institutes of Health, nationalinstituteondrugabuse

Study: Researchers develop ingestible capsule for insulin delivery

February 11, 2019 By Sarah Faulkner

A team of researchers from MIT developed an ingestible, blueberry-sized capsule that can deliver insulin orally. In animal models, the capsule lowered blood sugar levels and performed comparably with the traditional route of insulin delivery – injections. The capsule features a small needle made of freeze-dried, compressed insulin. The needle is attached to a compressed […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development Tagged With: Brigham & Women's Hospital, Massachusetts Institute of Technology, National Institutes of Health, Novo Nordisk

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 5
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS